Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jun;38(6):3299-3313.
doi: 10.1007/s12325-021-01754-2. Epub 2021 May 15.

Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study

Sergey A Boytsov  1 , Yuri P Burtsev  2 , Yunona V Khomitskaya  2 , Yuri A Karpov  3 ; STYLE study investigators
Collaborators, Affiliations
Observational Study

Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study

Sergey A Boytsov et al. Adv Ther. 2021 Jun.

Abstract

Introduction: Combination antihypertensive therapy is required by most patients to achieve guideline-recommended blood pressure (BP) goals. This study assessed the effectiveness and tolerability of bisoprolol/perindopril (Bis/Per) single-pill combination (SPC) in Russian patients with hypertension and coronary artery disease (CAD) treated in routine clinical practice.

Methods: STYLE (NCT03730116) was an open-label, uncontrolled, prospective observational study conducted in patients who were already receiving Bis/Per SPC, switched to SPC from Bis or Per monotherapy, or switched from a free combination of Bis and Per. Primary endpoint criteria were assessed at 1 and 3 months and included change in mean office systolic/diastolic blood pressure (SBP/DBP), proportion achieving target BP (< 140/90 mmHg), and measures of antianginal effectiveness.

Results: The full analysis set comprised 1892 subjects. Mean age was 61.9 ± 8.8 years, 53.2% were women, and mean durations of hypertension and CAD were 12.5 ± 7.9 and 7.2 ± 6.4 years, respectively. Mean SBP/DBP decreased by 22.3/11.0 mmHg and 31.5/15.9 mmHg at 1 and 3 months, respectively (P < 0.0001 vs baseline). Target BP was achieved by 49.2% and 86.7% of patients at 1 and 3 months, respectively. Reductions in mean number of angina attacks and nitrate consumption and improvements in heart rate were statistically significant. Treatment was well tolerated.

Conclusion: Treatment of patients with hypertension and CAD with Bis/Per SPC for 3 months was associated with significant decreases in SBP/DBP and a high proportion of patients achieving BP treatment goals. This was accompanied by an improvement in angina symptoms. Treatment was well tolerated in a broad patient population representative of those seen in everyday clinical practice.

Keywords: Angina; Arterial hypertension; Bisoprolol; Blood pressure; Coronary artery disease; Heart rate; Perindopril; Single-pill combination (SPC).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Change in mean blood pressure at visit 2 (1 month) and visit 3 (3 months) compared with visit 1 (inclusion visit). For both SBP and DBP, changes were statistically significant for visit 2 compared with visit 1 and for visit 3 compared with visit 1 (all P < 0.0001)
Fig. 2
Fig. 2
Proportion of subjects achieving blood pressure targets at visit 2 (1 month) and visit 3 (3 months)
Fig. 3
Fig. 3
Change in mean heart rate (HR) at visit 2 (1 month) and visit 3 (3 months) compared with visit 1 (inclusion visit)
Fig. 4
Fig. 4
Change in quality of life at visit 2 (1 month) and visit 3 (3 months) compared with visit 1 (inclusion visit). VAS visual analog scale
See this image and copyright information in PMC

References

    1. GBD 2015 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–1724. doi: 10.1016/S0140-6736(16)31679-8. - DOI - PMC - PubMed
    1. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–182. doi: 10.1001/jama.2016.19043. - DOI - PubMed
    1. Leon DA, Malyutina S, Kudryavtsev AV, et al. Dissecting hypertension in Russia: identifying aetiological and behavioural factors associated with treatment and control. Eur J Pub Health. 2018 doi: 10.1093/eurpub/cky212.876. - DOI
    1. Kontsevaya A, Kalinina A, Oganov R. Economic burden of cardiovascular diseases in the Russian Federation. Value Health Reg Issues. 2013;2(2):199–204. doi: 10.1016/j.vhri.2013.06.010. - DOI - PubMed
    1. Rotar O, Konradi A, Tanicheva A, et al. May measurement month 2017 in Russia: hypertension treatment and control, Europe. Eur Heart J Suppl. 2019;21(Suppl D):D101–D103. doi: 10.1093/eurheartj/suz068. - DOI - PMC - PubMed

Publication types

Associated data